CMMB News and Press, Chemomab Therapeutics Ltd. From 05/14/25

2025-05-14 18:48:08 ET Chemomab Therapeutics Ltd. (CMMB) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.46%. The average open to low on the day of earnings was -8.30%. The average ope...

2025-05-14 18:43:07 ET Chemomab Therapeutics Ltd. (CMMB) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CMMB stock price following earnings has averaged ±3.72% , with a median of 3.07...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

SPRING Trial Data Presented at Digestive Disease Week ® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Prog...

2025-04-28 11:31:02 ET Chemomab Therapeutics (NASDAQ: CMMB ) unveiled new clinical results that they will present at the EASL 2025 Annual Congress on May 7-10 , providing additional support for its lead drug candidate, nebokitug (CM-101), as a potential treatment for primary scl...

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment fo...

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd ., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the t...

David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC,...

Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key bio...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative ...